These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The role of growth factors in the development of diabetic retinopathy. Sharp PS Metabolism; 1995 Oct; 44(10 Suppl 4):72-5. PubMed ID: 7476315 [TBL] [Abstract][Full Text] [Related]
9. [The role of growth factors in proliferating diabetic retinopathy]. Gaudric A; Barritault D Journ Annu Diabetol Hotel Dieu; 1988; ():119-28. PubMed ID: 2459436 [No Abstract] [Full Text] [Related]
10. [Somatostatin analogues: a therapeutic tool in proliferative diabetic retinopathy?]. Vialettes B; Mallet B Journ Annu Diabetol Hotel Dieu; 1992; ():63-70. PubMed ID: 1353800 [No Abstract] [Full Text] [Related]
11. Novel role of erythropoietin in proliferative diabetic retinopathy. Takagi H; Watanabe D; Suzuma K; Kurimoto M; Suzuma I; Ohashi H; Ojima T; Murakami T Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S62-4. PubMed ID: 17481772 [TBL] [Abstract][Full Text] [Related]
12. Increased protein carbonylation of red blood cell membrane in diabetic retinopathy. Margetis PI; Antonelou MH; Petropoulos IK; Margaritis LH; Papassideri IS Exp Mol Pathol; 2009 Aug; 87(1):76-82. PubMed ID: 19379730 [TBL] [Abstract][Full Text] [Related]
13. [The role of transforming growth factor-beta in the pathogenesis of diabetic retinopathy]. Gacka M; Adamiec J Przegl Lek; 2006; 63(5):296-8. PubMed ID: 17036509 [TBL] [Abstract][Full Text] [Related]
14. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852 [TBL] [Abstract][Full Text] [Related]
15. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Wiedemann P Surv Ophthalmol; 1992; 36(5):373-84. PubMed ID: 1566240 [TBL] [Abstract][Full Text] [Related]
16. In vitro angiomodulatory activity of sera from type 2 diabetic patients with background retinopathy. Chorostowska-Wynimko J; Skopiński P; Szaflik J; Partyka I; Duda-Król B; Anuszewska E; Skopińska-Rózewska E J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():65-70. PubMed ID: 16204777 [TBL] [Abstract][Full Text] [Related]
17. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy. Vekasi J; Koltai K; Gaal V; Toth A; Juricskay I; Kesmarky G Clin Hemorheol Microcirc; 2008; 39(1-4):385-9. PubMed ID: 18503149 [TBL] [Abstract][Full Text] [Related]
18. High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins. Liinamaa MJ; Savolainen MJ Ann Med; 2008; 40(3):209-14. PubMed ID: 18382886 [TBL] [Abstract][Full Text] [Related]
19. [Occurrence of changes in the eye in diabetic retinopathy with significant myopia]. Dujić M; Misailović K; Nikolić Lj; Ignjacev M Srp Arh Celok Lek; 1998; 126(11-12):457-60. PubMed ID: 9921019 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]